2. Search Result
Search Result
Results for "

Resistance risk

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-164573
    Cyclobutrifluram

    		Succinate Dehydrogenase Fungal Infection
    Cyclobutrifluram is a succinate dehydrogenase inhibitor (SDHI) with mean EC50 of 0.025 μg/mL for F. fujikuroi. Cyclobutrifluram has superior antifungal activity and significantly inhibits mycelial growth of sensitive F. fujikuroi, but it induces resistance risk of F. fujikuroi, especially in mutations of amino acid substitutions H248L/Y of FfSdhB and G80R or A83V of FfSdhC2. Cyclobutrifluram can be used for rice bakanae disease (RBD) research .
    Cyclobutrifluram
  • HY-101453
    Ceefourin 1

    		P-glycoprotein Cancer
    Ceefourin 1 is a potent and highly selective multidrug resistance protein 4 (MRP4) inhibitor. Ceefourin 1 inhibits transport of a broad range of MRP4 substrates, yet is highly selective for MRP4 over other ABC transporters. Ceefourin 1 is a benzothiazol and primarily as a chemosensitizer for high-risk neuroblastoma .
    Ceefourin 1
  • HY-W250721A
    Carbomer 940

    CBM 940

    		 Biochemical Assay Reagents Others
    Carbomer 940 (CBM 940) is an acrylic acid polymer, which can be used as a thickening agent. Carbomer 940 provides a stable gel matrix, and exhibits good heat, light and microbial contamination resistance. Carbomer 940 shows high benzene content, which exists the risk as a carcinogen. Carbomer 940 facilitates the drug release and local application, which can be used in the pharmaceutical industry .
    Carbomer 940
  • HY-B1325
    Cefuroxime axetil

    		Bacterial Antibiotic Infection Inflammation/Immunology
    Cefuroxime axetil is an orally effective broad-spectrum β-lactam antibiotic that targets bacterial penicillin-binding proteins (PBPs, such as PBP3 and PBP1). Cefuroxime axetil inhibits cell wall synthesis, leading to bacterial lysis and death, with a minimum inhibitory concentration (MIC) of 0.12-4 mg/L for non-typeable Haemophilus influenzae (NTHi). Cefuroxime axetil is hydrolyzed by esterase to the active ingredient Cefuroxime (HY-B1256A) after oral absorption. Topical administration of Cefuroxime via bioadhesive nanoparticles (BNPs) can prolong the drug's retention time in the middle ear (≥7 days). Cefuroxime axetil can be used in the study of otitis media (especially NTHi infection). Cefuroxime axetil can achieve precise antibacterial effects through oral or topical nano-delivery systems, reducing systemic exposure and the risk of antibiotic resistance .
    Cefuroxime axetil
  • HY-116857
    Ditalimfos

    		Fungal Others
    Ditalimfos is an organophosphate fungicide. Ditalimfos is mainly used in agriculture to control fungal diseases of crops. Ditalimfos can be used for fungal resistance studies and risk assessment of residues in the environment .
    Ditalimfos
  • HY-N2406R
    Dihydrocaffeic acid (Standard)

    3,4-Dihydroxy-benzenepropanoic acid (Standard)

    		 Reference Standards p38 MAPK Endogenous Metabolite Reactive Oxygen Species (ROS) NO Synthase Inflammation/Immunology
    Ditalimfos (Standard) is the analytical standard of Ditalimfos. This product is intended for research and analytical applications. Ditalimfos is an organophosphate fungicide. Ditalimfos is mainly used in agriculture to control fungal diseases of crops. Ditalimfos can be used for fungal resistance studies and risk assessment of residues in the environment .
    Dihydrocaffeic acid (Standard)
  • HY-116857R
    Ditalimfos (Standard)

    		Reference Standards Fungal Others
    Ditalimfos (Standard) is the analytical standard of Ditalimfos. This product is intended for research and analytical applications. Ditalimfos is an organophosphate fungicide. Ditalimfos is mainly used in agriculture to control fungal diseases of crops. Ditalimfos can be used for fungal resistance studies and risk assessment of residues in the environment .
    Ditalimfos (Standard)
  • HY-169224
    SARS-CoV-2-IN-100

    		SARS-CoV Infection
    SARS-CoV-2-IN-100 (Compound 172) is an inhibitor of SARS-CoV-2, demonstrating broad-spectrum antiviral activity against various SARS-CoV-2 variants. SARS-CoV-2-IN-100 exhibits synergistic effects with Nirmatrelvir, which can reduce the risk of antiviral drug resistance .
    SARS-CoV-2-IN-100
  • HY-116497
    PH11

    		FAK Cancer
    PH11 is a novel focal adhesion kinase (FAK) inhibitor that rapidly induces apoptosis in TRAIL-resistant PANC-1 cells when combined with TRAIL, but has no effect on normal human fibroblasts. The study found that PH11 downregulates c-FLIP through inhibition of FAK and phosphatidylinositol-3-kinase (PI3K)/AKT pathways, thereby restoring the TRAIL apoptotic pathway, suggesting that this combination therapy may provide an attractive therapeutic strategy for the safe and effective treatment of pancreatic cancer. PH11 selectively inhibits c-FLIP expression by modulating upstream signaling pathways and may represent an innovative therapeutic strategy. Although further work is needed to fully elucidate the mechanism of PH11-induced TRAIL sensitization, we believe that our results will provide a new approach to target c-FLIP without the risk of interfering with caspase-8 processing, which could potentially lead to TRAIL resistance. This study also suggests a role for the FAK/AKT signaling pathway in regulating c-FLIP expression in TRAIL-induced apoptosis, and this understanding will provide important clues to control the resistance mechanism to optimize the potential of TRAIL-based pancreatic cancer treatment.
    PH11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: